{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T21:21:57Z","timestamp":1771190517099,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2000,6]]},"DOI":"10.1006\/ebeh.2000.0071","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:46:35Z","timestamp":1032191195000},"page":"153-159","source":"Crossref","is-referenced-by-count":19,"title":["Side Effect Profiles and Behavioral Consequences of Antiepileptic Medications"],"prefix":"10.1006","volume":"1","author":[{"given":"John R.","family":"Gates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/ebeh.2000.0071_RF1","series-title":"Frontiers of Clinical neuroscience. Vol. 12: Epilepsy and behavior","first-page":"37","article-title":"Effects of antiepileptic drugs on behavior","author":"Dodrill","year":"1991"},{"key":"10.1006\/ebeh.2000.0071_RF2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/ebeh.2000.0071_RF3","series-title":"Antiepileptic drugs. 4th ed","author":"Levy","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF4","series-title":"Antiepileptic drugs","first-page":"283","article-title":"Chemistry and biotransformation","author":"Browne","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-199504000-00008","article-title":"Folate deficiency, anticonvulsant drugs, and psychiatric morbidity","volume":"18","author":"Fr\u00f6scher","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.1006\/ebeh.2000.0071_RF6","series-title":"Antiepileptic drugs. 4th ed","first-page":"345","article-title":"Toxicity","author":"Bruni","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.152.3.413","article-title":"Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk","volume":"152","author":"Tohen","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF8","unstructured":"Holmes, G, L. Toxicity. In: Levy, R, H, Mattson, R, H, Meldrum, B, S, Penry, J, K, Dreifuss, F, E, editors. Antiepileptic drugs. 4th ed. New York, Raven Press, 1995: 567\u201379."},{"key":"10.1006\/ebeh.2000.0071_RF9","doi-asserted-by":"crossref","unstructured":"Tariot, P, N, Erb, R, Podgorski, C, A, Cox, C, Patel, S, Jakimovich, L, Irvine, C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry155::54\u201361.","DOI":"10.1176\/ajp.155.1.54"},{"key":"10.1006\/ebeh.2000.0071_RF10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1192\/bjp.167.5.698a","article-title":"Mania precipitated by carbamazepine withdrawal","volume":"167","author":"Scull","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF11","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1157.1995.tb00477.x","article-title":"Oculogyric crisis induced by carbamazepine","volume":"36","author":"Gormann","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF12","first-page":"300","article-title":"The effect of valproate on bipolar spectrum temperamental disorders","author":"Deltito","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF13","first-page":"765","article-title":"Relation of serum valproate concentration to response in mania","author":"Bowden","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF14","doi-asserted-by":"crossref","unstructured":"Kavoussi, R, J, Coccaro, E, F. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry59::676\u201380.","DOI":"10.4088\/JCP.v59n1206"},{"key":"10.1006\/ebeh.2000.0071_RF15","series-title":"Antiepileptic drugs. 4th ed","first-page":"641","article-title":"Toxicity","author":"Dreifuss","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archneur.1982.00510210061016","article-title":"Asymptomatic hyperammonemia in patients receiving valproic acid","volume":"39","author":"Murphy","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1006\/ebeh.2000.0071_RF17","first-page":"529","article-title":"Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults","volume":"56","author":"Buzan","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000433-199503000-00014","article-title":"Fatal acute pancreatitis caused by valproic acid","volume":"16","author":"Evans","year":"1995","journal-title":"Am J Forens Med Pathol"},{"key":"10.1006\/ebeh.2000.0071_RF19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1528-1157.1979.tb04853.x","article-title":"Stupor following administration of valproic acid to patients receiving other antiepileptic drugs","volume":"20","author":"Sackellares","year":"1979","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.410380423","article-title":"Reversible dementia and apparent brain atrophy during valproate therapy","volume":"38","author":"Papazian","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1006\/ebeh.2000.0071_RF21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00306271","article-title":"Antiepileptic therapy and behavior disturbances in children","volume":"9","author":"Domizo","year":"1993","journal-title":"Child's Nervous System"},{"key":"10.1006\/ebeh.2000.0071_RF22","unstructured":"Kalachnik, J, E, Hanzel, T, E, Educational bulletin: Report on the behavioral side effects of barbiturate antiepileptic drugs. A report by the Office of the Ombudsman for Mental Health and Mental Retardation, State of Minnesota, 1995."},{"key":"10.1006\/ebeh.2000.0071_RF23","first-page":"374","article-title":"Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavior measurement techniques","volume":"33","author":"Kalachnik","year":"1995","journal-title":"Ment Retard"},{"key":"10.1006\/ebeh.2000.0071_RF24","series-title":"Antiepileptic drugs. 4th ed","first-page":"409","article-title":"Toxicity","author":"Cramer","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF25","series-title":"Antiepileptic drugs. 4th ed","first-page":"817","article-title":"Clinical use","author":"Theodore","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF26","first-page":"32","article-title":"Psychological disturbance as a contributing factor for felbamate discontinuation","volume":"35","author":"Mason","year":"1994","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF27","series-title":"Antiepileptic drugs. 4th ed","first-page":"857","article-title":"Toxicity","author":"Ramsay","year":"1995"},{"key":"10.1006\/ebeh.2000.0071_RF28","first-page":"71","article-title":"Gabapentin in a medically refractory epilepsy population: seizure response and unusual side effects","volume":"36","author":"Doherty","year":"1995","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1157.1996.tb00598.x","article-title":"Gabapentin associated with aggressive behavior in pediatric patients with seizures","volume":"37","author":"Tallian","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.166.5.679b","article-title":"Hypomania induced by gabapentin","volume":"166","author":"Short","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1006\/ebeh.2000.0071_RF31","first-page":"166","article-title":"Efficacy and dosing of lamotrigine in a medically refractory epilepsy population","volume":"37","author":"Gates","year":"1996","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF32","first-page":"55","article-title":"Role of topiramate (Topamax) in adults with intractive epilepsy, mental retardation, and developmental disabilities","volume":"39","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF33","series-title":"Physician's desk reference","year":"2000"},{"key":"10.1006\/ebeh.2000.0071_RF34","unstructured":"Mosby's GenR, x, Update 1, 1998. Topiramate 3312."},{"key":"10.1006\/ebeh.2000.0071_RF35","first-page":"52","article-title":"Effect of topiramate on cognitive test performance","volume":"40","author":"Farnham","year":"1999","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF36","first-page":"250","article-title":"Comparative cognitive effects of topiramate, gabapentin, and lamotrigine: an acute and steady-state dosing study in healthy young adults","volume":"39","author":"Sinclair","year":"1998","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF37","first-page":"60","article-title":"Use of topiramate in the cognitively impaired","volume":"40","author":"Doherty","year":"1999","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF38","first-page":"56","article-title":"Post-marketing experience with tiagabine","volume":"39","author":"French","year":"1998","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF39","unstructured":"Clinical Pharmacology, November 1997, (Gabitril) from, www. rxabbott.com."},{"key":"10.1006\/ebeh.2000.0071_RF40","unstructured":"Data on file, ucb Pharma (Athena Neurosciences), 2000."},{"key":"10.1006\/ebeh.2000.0071_RF41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1006\/ebeh.2000.0071_RF42","unstructured":"Trileptal Summary of Product Characteristics, Ciba\u2013Geigy, Basel, March 24, 1993."},{"key":"10.1006\/ebeh.2000.0071_RF43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1528-1157.1994.tb02930.x","article-title":"Hyponatremia associated with carbamazepine and oxcarbamazepine therapy: a review","volume":"35","author":"Van Amelsvoort","year":"1994","journal-title":"Epilepsia"},{"key":"10.1006\/ebeh.2000.0071_RF44","unstructured":"Data on file, Novartis, 2000."},{"key":"10.1006\/ebeh.2000.0071_RF45","unstructured":"Gates, J, R, Summary: zonisamide. In, Fifth Eilat Conference on New Antiepileptic Drugs, Eilat, Israel, June 2000, in press."},{"key":"10.1006\/ebeh.2000.0071_RF46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1527-3458.1998.tb00075.x","article-title":"Zonisamide: pharmacology and clinical efficacy in epilepsy","volume":"4","author":"Masuda","year":"1998","journal-title":"CNS Drug Rev"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505000900714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505000900714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T02:53:58Z","timestamp":1557370438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505000900714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["S1525505000900714"],"URL":"https:\/\/doi.org\/10.1006\/ebeh.2000.0071","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}